▪ Full-Year 2024 Revenue Guidance Range of $58.5 to $61.5 Billion Includes Expected Contribution from Seagen Acquisition
- Anticipates Approximately $8 Billion in Revenues for Comirnaty and Paxlovid
- Seagen Expected to Contribute Approximately $3.1 Billion of Revenues
▪ Expects Full-Year 2024 Operational [i.e. constant currency] Revenue Growth of 8%-10% Including Seagen Contribution and Excluding Comirnaty and Paxlovid Revenues, and 3%-5% Excluding Both Seagen Contribution and Comirnaty and Paxlovid Revenues
▪ 2024 Adjusted Diluted [i.e. non-GAAP] EPS Guidance Range of $2.05 to $2.25 Includes Expected Impact of Seagen Acquisition
▪ Enterprise-Wide Cost Realignment Program Now Expected to Deliver Annual Net Cost Savings of at Least $4.0 Billion, an Incremental $500 Million Versus Mid-Point of Guidance Range Provided on August 1, 2023
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.